Deutsche Bank AG boosted its position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) by 67.6% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,072,239 shares of the company's stock after purchasing an additional 835,600 shares during the quarter. Deutsche Bank AG owned about 0.81% of Maravai LifeSciences worth $4,580,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. ProShare Advisors LLC lifted its position in Maravai LifeSciences by 89.8% in the 4th quarter. ProShare Advisors LLC now owns 55,488 shares of the company's stock valued at $302,000 after purchasing an additional 26,251 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Maravai LifeSciences by 22.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 251,214 shares of the company's stock valued at $1,369,000 after purchasing an additional 45,454 shares during the last quarter. SG Americas Securities LLC lifted its position in Maravai LifeSciences by 2,005.9% in the 1st quarter. SG Americas Securities LLC now owns 695,907 shares of the company's stock valued at $1,538,000 after purchasing an additional 662,861 shares during the last quarter. Northern Trust Corp lifted its position in Maravai LifeSciences by 5.3% in the 4th quarter. Northern Trust Corp now owns 1,070,425 shares of the company's stock valued at $5,834,000 after purchasing an additional 53,474 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in Maravai LifeSciences by 12.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 70,828 shares of the company's stock valued at $387,000 after purchasing an additional 7,946 shares during the last quarter. 50.25% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Several analysts recently weighed in on MRVI shares. Royal Bank Of Canada cut their price objective on shares of Maravai LifeSciences from $7.00 to $5.00 and set an "outperform" rating on the stock in a research report on Tuesday, August 12th. Robert W. Baird decreased their target price on shares of Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating for the company in a research report on Tuesday, May 13th. Finally, Craig Hallum decreased their target price on shares of Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. Four analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Maravai LifeSciences has a consensus rating of "Hold" and a consensus price target of $5.75.
Check Out Our Latest Stock Analysis on MRVI
Maravai LifeSciences Price Performance
Shares of MRVI traded up $0.0650 during mid-day trading on Friday, hitting $2.4550. The company's stock had a trading volume of 188,725 shares, compared to its average volume of 2,396,446. The firm has a 50-day moving average price of $2.44 and a 200 day moving average price of $2.53. The stock has a market capitalization of $625.19 million, a price-to-earnings ratio of -1.81 and a beta of 0.28. The company has a debt-to-equity ratio of 0.68, a current ratio of 5.16 and a quick ratio of 4.49. Maravai LifeSciences Holdings, Inc. has a fifty-two week low of $1.66 and a fifty-two week high of $9.60.
Maravai LifeSciences Profile
(
Free Report)
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Featured Articles
Before you consider Maravai LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maravai LifeSciences wasn't on the list.
While Maravai LifeSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access